The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study
Authors: M. E Miller, D. E Bonds, H. C Gerstein, E. R Seaquist, R. M Bergenstal, J. Calles-Escandon, R D. Childress, T. E Craven, R. M Cuddihy, G. Dailey, M. N Feinglos, F. Ismail-Beigi, J. F Largay, P. J O'Connor, T. Paul, P. J Savage, U. K Schubart, A. Sood, S. Genuth
Journal: BMJ (2010)

<b>Objectives</b> To investigate potential determinants of severe hypoglycaemia, including baseline characteristics, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the association of severe hypoglycaemia with levels of glycated haemoglobin (haemoglobin A<sub>1C</sub>) achieved during therapy. <b>Design</b> Post hoc epidemiological analysis of a double 2×2 factorial, randomised, controlled trial. <b>Setting</b> Diabetes clinics, research clinics, and primary care clinics. <b>Participants</b> 10 209 of the 10 251 participants enrolled in the ACCORD study with type 2 diabetes, a haemoglobin A<sub>1C</sub> concentration of 7.5% or more during screening, and aged 40-79 years with established cardiovascular disease or 55-79 years with evidence of significant atherosclerosis, albuminuria, left ventricular hypertrophy, or two or more additional risk factors for cardiovascular disease (dyslipidaemia, hypertension, current smoker, or obese). <b>Interventions </b>Intensive (haemoglobin A<sub>1C</sub> &lt;6.0%) or standard (haemoglobin A<sub>1C</sub> 7.0-7.9%) glucose control. <b>Main outcome measures</b> Severe hypoglycaemia was defined as episodes of "low blood glucose" requiring the assistance of another person and documentation of either a plasma glucose less than 2.8 mmol/l (&lt;50 mg/dl) or symptoms that promptly resolved with oral carbohydrate, intravenous glucose, or glucagon. <b>Results</b> The annual incidence of hypoglycaemia was 3.14% in the intensive treatment group and 1.03% in the standard glycaemia group. We found significantly increased risks for hypoglycaemia among women (P=0.0300), African-Americans (P&lt;0.0001 compared with non-Hispanic whites), those with less than a high school education (P&lt;0.0500 compared with college graduates), aged participants (P&lt;0.0001 per 1 year increase), and those who used insulin at trial entry (P&lt;0.0001). For every 1% unit decline in the haemoglobin A<sub>1C</sub> concentration from baseline to 4 month visit, there was a 28% (95% CI 19% to 37%) and 14% (4% to 23%) reduced risk of hypoglycaemia requiring medical assistance in the standard and intensive groups, respectively. In both treatment groups, the risk of hypoglycaemia requiring medical assistance increased with each 1% unit increment in the average updated haemoglobin A<sub>1C</sub> concentration (standard arm: hazard ratio 1.76, 95% CI 1.50 to 2.06; intensive arm: hazard ratio 1.15, 95% CI 1.02 to 1.21). <b>Conclusions</b> A greater drop in haemoglobin A<sub>1C</sub> concentration from baseline to the 4 month visit was not associated with an increased risk for hypoglycaemia. Patients with poorer glycaemic control had a greater risk of hypoglycaemia, irrespective of treatment group. Identification of baseline subgroups with increased risk for severe hypoglycaemia can provide guidance to clinicians attempting to modify patient therapy on the basis of individual risk. <b>Trial registration</b> ClinicalTrials.gov number NCT00000620.